在遗传性抗素III缺乏症中的死亡率 - - 1830年至1989年
F R Rosendaal1, H Heijboer, E Briët
1Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands.
Lancet (London, England)
|February 2, 1991
概括
遗传性抗素III (AT-III) 缺乏似乎不会增加死亡风险. 预防性抗凝剂不推给具有AT-III缺乏症的个人.
科学领域:
- 医学研究 医学研究
- 遗传学 是一个遗传学.
- 血液学 血液学 血液学
背景情况:
- 抗血-III (AT-III) 是血液凝固级联中的一个关键蛋白质.
- 遗传AT-III缺乏症是发生血栓事件的已知危险因素.
- 缺乏AT-III对整体死亡率的影响需要进一步研究.
研究的目的:
- 调查遗传性抗素III缺乏症与全因死亡率之间的关联.
- 评估AT-III缺乏症患者预防性抗凝药的必要性.
主要方法:
- 研究了来自十个家庭的171名确诊遗传AT-III缺乏症的个体.
- 根据AT-III度或孟德尔遗传,将73个人归类为确定的缺陷.
- 通过将记录的死亡率与一般人口预期的死亡率进行比较来评估死亡率,并根据年龄,性别和时间进行调整.
主要成果:
- 在研究队列中,共记录了64例死亡.
- 观察到的死亡率没有超过一般人口的预期死亡率,考虑到年龄,性别和日历时期.
- 在遗传AT-III缺乏症患者中没有发现统计学上显著的死亡率增加.
结论:
- 遗传性抗素III缺乏与过度死亡率无关.
- 目前的证据不支持对所有AT-III缺乏症患者进行预防性抗凝药的政策.
- 进一步的研究可能会完善特定患者子组的管理策略.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...